FDA launches program for rare diseases targeting ‘significant’ unmet need
Regulatory NewsJoanne S. Eglovitch
Biologics License Application (BLA)Biologics/ biosimilars/ vaccinesBiotechnologyCBERCDERClinical TrialsLeadershipPharmaceuticalsProduct developmentRegulatory Intelligence/PolicyTechnical documentationUnited StatesUS Food and Drug Administration (FDA)